PDRN CareDermal Wound Contraction
Dr. Sarah Chen
PhD, Molecular Biology
Wound contraction is a biomechanical process during the proliferative phase of wound healing in which specialized contractile cells β myofibroblasts β generate mechanical force to draw wound margins together, reducing the area of exposed tissue that must be repaired by new matrix deposition and re-epithelialization [1,3].
Definition
Wound contraction is a biomechanical process during the proliferative phase of wound healing in which specialized contractile cells β myofibroblasts β generate mechanical force to draw wound margins together, reducing the area of exposed tissue that must be repaired by new matrix deposition and re-epithelialization [1][3]. In skin wounds, contraction typically accounts for 40-80% of wound closure depending on anatomical location, wound depth, and species [1]. PDRN influences wound contraction by modulating myofibroblast activity and the inflammatory environment that governs their differentiation and persistence [2][4].
The Myofibroblast
Origin and Differentiation
Myofibroblasts are not a permanent cell population β they differentiate from resident dermal fibroblasts (and to a lesser extent from pericytes, fibrocytes, and epithelial cells via epithelial-mesenchymal transition) in response to wound healing signals [1][3]. The differentiation process occurs in two stages:
- Proto-myofibroblast β Fibroblasts exposed to mechanical tension from the provisional wound matrix develop cytoplasmic stress fibers containing beta-actin and gamma-actin, generating modest contractile force [1][3]
- Mature myofibroblast β Under the influence of TGF-beta1, mechanical stress, and the ED-A splice variant of fibronectin, proto-myofibroblasts upregulate alpha-smooth muscle actin (alpha-SMA), the defining molecular marker that confers substantially greater contractile force [1][3]
Contractile Mechanism
Myofibroblasts generate contraction through a mechanism distinct from smooth muscle cells [1]. Alpha-SMA-containing stress fibers connect to the extracellular matrix via focal adhesions (specialized integrin-based anchor points), and their contraction transmits force directly to the surrounding collagen network [1][3]. This is not a rhythmic contraction like muscle but a sustained, incremental shortening that progressively reduces wound area over days to weeks [1]. The total force generated by a wound bed of myofibroblasts is substantial β comparable to the tensile strength of smooth muscle tissue [1].
Fate After Wound Closure
Once wound contraction is complete and the tissue is mechanically stable, myofibroblasts must be eliminated to prevent pathological fibrosis [1][3]. Under normal circumstances, myofibroblasts undergo apoptosis β programmed cell death triggered by the resolution of pro-survival signals (reduced TGF-beta, decreased mechanical tension) [1][3]. Failure of myofibroblast apoptosis leads to continued contraction and excessive collagen deposition, resulting in hypertrophic scars, contractures, or organ fibrosis [3].
The Wound Contraction Process
Timeline
Wound contraction begins approximately 4-5 days after injury, when granulation tissue has formed and myofibroblast differentiation is underway [1]. The most active contraction phase spans days 5-15, with the wound perimeter advancing centrally at a rate of approximately 0.6-0.75 mm per day in full-thickness skin wounds [1][3]. Contraction slows as the wound becomes smaller and the mechanical tension across the wound bed equilibrates [1].
Regulation
Multiple factors modulate the rate and extent of wound contraction [1][3]:
- TGF-beta1 β The primary driver of myofibroblast differentiation and the sustained expression of alpha-SMA [1][3]
- Mechanical tension β Required for both myofibroblast differentiation and maintenance of the contractile phenotype [1]
- Inflammatory mediators β Persistent inflammation prolongs myofibroblast activity, while appropriate inflammation resolution triggers apoptosis [3]
- Matrix composition β The stiffness and architecture of the provisional matrix influence the efficiency of force transmission [1]
PDRN and Wound Contraction
PDRN influences wound contraction through multiple interconnected mechanisms [2][4][5]:
Accelerating the Proliferative Phase
PDRN stimulates fibroblast proliferation and migration into the wound bed through adenosine A2A receptor activation, ensuring that an adequate pool of precursor cells is available for myofibroblast differentiation [2][4]. In diabetic wound models where fibroblast recruitment is impaired, PDRN treatment restored the cellular populations necessary for effective contraction [2].
Modulating Inflammation
The timing and quality of wound contraction depend critically on the inflammatory environment [2][4]. PDRN's anti-inflammatory action β suppression of TNF-alpha, IL-6, and IL-1beta β helps transition the wound from the inflammatory phase to the proliferative phase where myofibroblast differentiation and contraction can proceed efficiently [2][4]. In chronic wounds, where persistent inflammation stalls contraction, this transition is particularly valuable [4].
Supporting Matrix Quality
By promoting organized collagen deposition and adequate angiogenesis in the wound bed, PDRN creates a mechanically competent matrix that supports efficient force transmission during contraction [2][5]. A well-vascularized granulation tissue with organized collagen fibers allows myofibroblasts to generate and transmit contractile force more effectively than the disorganized, ischemic tissue typical of impaired wounds [2].
Promoting Appropriate Resolution
Because PDRN reduces the chronic inflammatory signals that sustain myofibroblast activity beyond the point of wound closure, it may help facilitate the timely apoptosis of myofibroblasts that is necessary to prevent excessive contraction and fibrosis [4][5]. This anti-fibrotic potential is an area of active investigation, with implications for scar quality in both surgical and aesthetic contexts [4].
Clinical Significance
Understanding wound contraction is relevant to both regenerative medicine and aesthetic dermatology [2][4]:
- Chronic wound closure β PDRN's ability to restore the cellular and matrix conditions necessary for contraction makes it valuable in diabetic ulcers and other non-healing wounds [2]
- Scar prevention β By supporting efficient contraction followed by appropriate myofibroblast apoptosis, PDRN may reduce hypertrophic scar formation [4][5]
- Post-procedure healing β After deep ablative procedures, PDRN promotes organized wound contraction that contributes to smoother, less contracted healing [4]
- Dermal remodeling β The same myofibroblast biology that drives wound contraction contributes to the tissue tightening effects observed in PDRN skin rejuvenation treatments [4][5]
References
- [1]Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349-363. doi:10.1038/nrm809
- [2]Galeano M, Bitto A, Altavilla D, et al.. Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair Regen. 2008;16(2):208-217. doi:10.1111/j.1524-475X.2008.00361.x
- [3]Hinz B, Phan SH, Thannickal VJ, et al.. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340-1355. doi:10.1016/j.ajpath.2012.02.004
- [4]Squadrito F, Bitto A, Irrera N, et al.. Pharmacological Activity and Clinical Use of PDRN. Curr Pharm Des. 2017;23(27):3948-3957. doi:10.2174/1381612823666170516153716
- [5]Veronesi F, Dallari D, Sabbioni G, Carubbi C, Martini L, Fini M. Polydeoxyribonucleotides (PDRNs): From Physical Chemistry to Biological Activities and Clinical Applications. Int J Mol Sci. 2017;18(9):1927. doi:10.3390/ijms18091927